Biocon Biologics completes integration of acquired biosimilars business in 70 countries in Emerging Markets

Following the deal closure in November 2022, this marks the first wave of countries where Viatris' operations have fully transitioned to Biocon Biologics. A robust integration plan has ensured a seamless transition of partners, people, systems, and processes across these countries.

from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/XhU0lSD
via